The Best of FierceBiotech 2010

Over the past year, a steadily growing life sciences team at FierceMarkets has presented a long lineup of special reports on the biopharma industry. Some you're familiar with; for instance, this year marked our eighth annual Fierce 15. But we also followed up with new reports on some novel subjects, such as the most notable women in biotech or a look at the top Phase III failures of the year and much, much more.

Today's issue is dedicated to our most popular special reports of the year. Check them out and let us know what you'd like to see in 2011. - John Carroll (email | twitter)

P.S. For those of you who don't subscribe to our newsletter, you can see all of the 2010 special reports here.

Suggested Articles

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.

Bluebird bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.